Mogelijk gemaakt door Google TranslateTranslate
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Latest Press Releases
View all
TimeHeadline
10h agoDelivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
11h agoRefers to Item 7 on the agenda: Report on the audit of the consolidated financial statements of Grupa Kęty SA
13h agoThe 4th BOCHK Science and Technology Innovation Prize Award Ceremony Concludes with Great Success
20h agoBuffalo Potash Files Annual Information Form and New Technical Report
21h agoIonik Announces 30-Day Extension of Senior Debt Facility
Pharvaris N.v. logo

Pharvaris N.v.

About

29.68USD-0.86 -2.82%
Closed • Updated at 00:25 GMT+00:00
Market Cap$1.94B
Volume291.1K
Beta0.61
RSI50.52
Health TechnologyBiotechnology

Pharvaris N.v. — investor relations, events, news, and company updates on 6ix.

Latest News

May 11 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 8 2026
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
Apr 20 2026
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
Apr 2 2026
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 11 2026
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

Community Chat

Ask AI

Try asking
6ix6ixAIEvents